Podcasts about discontinuation

Interview with Sameer Jauhar, PhD, author of Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. Hosted by John Torous, MD. Related Content: Incidence and Nature of Antidepressant Discontinuation Symptoms

Interview with Sameer Jauhar, PhD, author of Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. Hosted by John Torous, MD. Related Content: Incidence and Nature of Antidepressant Discontinuation Symptoms

Jaffa fans are coming to grips with the news the orange-coated chocolate treat will soon be no more. Confectionery company RJs has this week confirmed it stopped making the long-time Kiwi favourite earlier this year, and they'll soon vanish from shop shelves. Reporter Jimmy Ellingham visited the home of the Jaffa, the RJs outlet store and factory in Levin, to ask sweet-toothed visitors stocking up on packets of the sweeties how they feel about the end of the Jaffa.

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode, we discuss the critical challenges of benzodiazepine discontinuation, exploring Benzodiazepine-Induced Neurological Dysfunction (BIND) and effective support strategies for patients experiencing protracted withdrawal. What can clinicians do when over 50% of patients report finding more help from online forums than from medical professionals? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Strategies for Successful Benzodiazepine Deprescribing Beyond Benzodiazepine Discontinuation: Understanding Life Effects and Support Strategies

In deze aflevering van de Anti-dieet podcast deel ik graag de eerste aflevering van het nieuwe seizoen van Intuïtief Eten de Podcast met je. Sinds kort mag ik ook deze podcast hosten en in de eerste aflevering gingen Femke, Evita en ik in gesprek over Ozempic (ofwel afslankmedicatie) . Wat zijn de feiten, hoe werkt het nu eigenlijk en hoe gaat het samen met intuïtief eten? Meer informatie over het Centrum voor Intuïtief Eten, de gratis tools en downloads, boeken, coaching en opleidingen vind je op deze ⁠website⁠. En volg je ons al op de ⁠socials⁠? Meer informatie over mijn eigen aanbod, gratis downloads en introductielessen vind je op mijn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ en op mijn socials ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@voedingspsycholoog.⁠⁠⁠⁠Overzicht van de artikelen waarover we het hadden tijdens deze aflevering:⁠Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States - PMC⁠⁠Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data⁠⁠Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects - Sørensen - 2025 - Diabetes, Obesity and Metabolism - Wiley Online Library⁠⁠Semaglutide for the treatment of overweight and obesity: A review⁠⁠A systematic review of the psychosocial correlates of intuitive eating among adult women - ScienceDirect⁠⁠What's Wrong With the ‘War on Obesity?' A Narrative Review of the Weight-Centered Health Paradigm and Development of the 3C Framework to Build Critical Competency for a Paradigm Shift - Lily O'Hara, Jane Taylor, 2018⁠⁠Obesity treatment: Weight loss versus increasing fitness and physical activity for reducing health risks - PubMed⁠⁠How and why weight stigma drives the obesity ‘epidemic' and harms health | BMC Medicine | Full Text⁠Profiel van endocrinoloog Gregory Dodell: ⁠Instagram

Dr. Halley Alexander and Dr. Samuel W. Terman discuss patients' perceived seizure risk, seizure risk tolerance, and risk counseling techniques.  Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200475 

Dr. Halley Alexander talks with Dr. Samuel W. Terman about patients' perceived seizure risk, seizure risk tolerance, and risk counseling techniques.  Read the related article in Neurology® Clinical Practice.  Disclosures can be found at Neurology.org. 

Commentary by Dr. Meixiang Xiang.

In this episode, we explore evidence-based strategies for successful benzodiazepine tapering with addiction psychiatrist Dr. Alexis Ritvo. How can clinicians minimize withdrawal effects while supporting patients through this challenging process? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing Understanding the Principles of Benzodiazepine Tapering

Nucala gains new indication; the FDA are set to require placebo-controlled trials to evaluate COVID-19 vaccines; pruritus reported following discontinuation of antihistamines; oral carbapenem antibiotic looks promising for cUTIs; investigational celiac disease Tx gets Fast Tracked

A News Roundup episode, and an episode of two halves.  We start with a discussion of the recent public Oval Office meeting between Trump and Cyril Ramaphosa, in which Trump harangued the South African president with accusations of 'white genocide' based on 'evidence' which tracks straight back to people in our usual wheelhouse.  Then we move on to a chat about the recent decision by language learning app Duolingo to replace loads of their contributors with AI, plus some dismaying news about Babbel, leading to a discussion of the impending AI jobs crisis.  Then we cap it off with an odd flex for us... a feel good story! Episode Notes: Trump spreads racist South African Farm Murders Memes in meeting with Ramaphosa Trump/Ramaphosa meeting: https://www.youtube.com/watch?v=3TLkZv3gzO0 Response: https://www.cnn.com/2025/05/21/politics/video/trump-ramaphosa-south-africa-video-larry-madowo-vrtc * A check of Trump's false claims about white genocide in South Africa | Reuters https://www.reuters.com/world/us/trump-makes-false-claims-white-genocide-south-africa-during-ramaphosa-meeting-2025-05-21/ Trump's evidence of South Africa ‘white genocide' contains images from DR Congo – The Irish Times https://www.irishtimes.com/world/africa/2025/05/23/trumps-evidence-of-south-africa-white-genocide-contains-images-from-dr-congo/ Trump confronted South African president with ‘evidence' of genocide – here's what the video really showed | The Independent https://www.independent.co.uk/news/world/americas/us-politics/trump-south-africa-genocide-video-b2755625.html Trump ambushes South African president with video and false claims of anti-white racism | Trump administration | The Guardian https://www.theguardian.com/us-news/2025/may/21/trump-south-africa-president-meeting?utm_source=dlvr.it&utm_medium=bluesky&CMP=bsky_gu What's Behind Trump's South Africa Obsession? | Benjamin Fogel | TMR https://youtu.be/gR_gwPI5l-0?si=QfWeEuoosYeUD-JG South Africa to offer Elon Musk Starlink deal ahead of Trump meeting | Business Insider Africa https://africa.businessinsider.com/local/markets/south-africa-to-offer-elon-musk-starlink-deal-ahead-of-trump-meeting/v0k8bxk?op=1 White Nationalists Praise Trump's Promotion Of White Genocide Conspiracy Theory – Angry White Men https://angrywhitemen.org/2025/05/22/white-nationalists-praise-trumps-promotion-of-white-genocide-conspiracy-theory/ Exclusive: Trump Shared Racist, Flat-Earth Facebook Account With South African President https://www.meidasplus.com/p/exclusive-trump-shared-racist-flat Roaming Charges: White Lies About White Genocide - CounterPunch.org https://www.counterpunch.org/2025/05/23/white-lies-about-white-genocide/ DR Congo: Killings, Rapes by Rwanda-Backed M23 Rebels | Human Rights Watch https://www.hrw.org/news/2023/06/13/dr-congo-killings-rapes-rwanda-backed-m23-rebels As Goma ceasefire largely holds, Congo rushes to bury bodies from rebel offensive | Reuters https://www.reuters.com/world/africa/east-congo-city-goma-rushes-bury-bodies-after-rebel-offensive-2025-02-04/ A white nationalist moved to Idaho in search of an ‘ethnic enclave.' He's not alone. https://www.spokesman.com/stories/2022/jul/21/a-white-nationalist-moved-to-idaho-in-search-of-an/ * Duolingo Replacing Contract Workers With AI The Verge, “Duolingo will replace contract workers with AI” https://www.theverge.com/news/657594/duolingo-ai-first-replace-contract-workers “AI isn't just a productivity boost,” von Ahn says. “It helps us get closer to our mission. To teach well, we need to create a massive amount of content, and doing that manually doesn't scale. One of the best decisions we made recently was replacing a slow, manual content creation process with one powered by AI. Without AI, it would take us decades to scale our content to more learners. We owe it to our learners to get them this content ASAP.” von Ahn's email follows a similar memo Shopify CEO Tobi Lütke sent to employees and recently shared online. In that memo, Lütke said that before teams asked for more headcount or resources, they needed to show “why they cannot get what they want done using AI.” Fortune, “Duolingo CEO walks back AI-first comments: ‘I do not see AI as replacing what our employees do'” “To be clear: I do not see AI as replacing what our employees do (we are in fact continuing to hire at the same speed as before),” he wrote. “I see it as a tool to accelerate what we do, at the same or better level of quality. And the sooner we learn how to use it, and use it responsibly, the better off we will be in the long run.” Babbel quietly ending Babbel Live Babbel Support, “Discontinuation of Babbel Live” https://support.babbel.com/hc/en-us/articles/26749152437522-Discontinuation-of-Babbel-Live “Babbel Live was introduced in 2021. Knowing the power of human teachers, we aimed to offer our learners this experience from their homes. Over time, however, we did see a clear trend: the majority of them did not accept Babbel Live as part of their language learning path, making it impossible for us to sustain it as a business. This change will help us achieve our goal of helping you become fluent in your new language quickly by enabling us to focus on improving our app, which most learners, especially beginners, prefer.” Boycott Over Upcoming E-sports Event in Riyadh Makes Geoguessr Change Its Stance Geoguessr Community Protests Esports World Cup by Disabling Popular Maps. https://www.si.com/esports/news/geoguessr-protests-esports-world-cup Statement from Feneb, one of the World Championship players, about his decision to boycott the Riyadh event. https://discord.com/channels/1003591679644807229/1026965093331779634/1375003211513204746 “The decision to participate in the Esports World Cup, which is directly funded by the Saudi Arabian government in an effort to distract public attention from the above human rights violations, is thus directly incompatible with any stated aims by GeoGuessr to promote an inclusive and diverse community, and extremely disappointing. I also do not want to dismiss the issue of hosting a tournament in Saudi Arabia, regardless of whether the event is directly run by the Saudi government or not. It is completely unnecessary to host a tournament in a country which some current or possible future world league players would be unable to travel to safely.” Statement from Geoguessr regarding their decision to reverse the event in Riyadh (Reddit) https://www.reddit.com/r/geoguessr/comments/1ksky0k/geoguessr_is_withdrawing_from_the_esports_world/ Geoguessr challenge links: (Standard) World Map https://www.geoguessr.com/challenge/MIJFcVhIFNpVapVs https://www.geoguessr.com/challenge/sedHxYRoMPdmFxdZ https://www.geoguessr.com/challenge/eIRYCYBhuUUBVIT2 An Official World https://www.geoguessr.com/challenge/tK9A8O1KUXQfZgCu https://www.geoguessr.com/challenge/NGYJ4uk0WhxNR5Ui https://www.geoguessr.com/challenge/Yc4uD6P8lFISKIgb A Community World https://www.geoguessr.com/challenge/B87Y20LMvmtDvUwN https://www.geoguessr.com/challenge/I9ub9gc9CmoEQpjn https://www.geoguessr.com/challenge/ZwKxnW3Ms9UTZZt6 * The AI jobs crisis is here, now - by Brian Merchant https://www.bloodinthemachine.com/p/the-ai-jobs-crisis-is-here-now Something Alarming Is Happening to the Job Market - The Atlantic https://www.theatlantic.com/economy/archive/2025/04/job-market-youth/682641/  Show Notes: Please consider donating to help us make the show and stay ad-free and independent.  Patrons get exclusive access to at least one full extra episode a month plus all backer-only back-episodes. Daniel's Patreon: https://www.patreon.com/danielharper/posts Jack's Patreon: https://www.patreon.com/user?u=4196618&fan_landing=true IDSG Twitter: https://twitter.com/idsgpod Daniel's Twitter: @danieleharper Jack's (Locked) Twitter: @_Jack_Graham_ Jack's Bluesky: @timescarcass.bsky.social Daniel's Bluesky: @danielharper.bsky.social IDSG on Apple Podcasts: https://podcasts.apple.com/us/podcast/i-dont-speak-german/id1449848509?ls=1

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 67 Which Antidepressants Have the Highest Risk of Discontinuation Symptoms?

In this episode, the Surgical Endoscopy team, accompanied by Chief Medical Officer Dr. Brian Dunkin of Boston Scientific, review primary and revisional endoscopic treatment options for bariatric patients. They focus on the emerging data available for procedures such as endoscopic sleeve gastroplasty (ESG) and endoscopic gastrojejunal revision (EGJR) and offer technical tips on how to perform the procedures. In addition, they discuss accessibility challenges for patients and provide insight into the future direction of bariatric endoscopy as a field.  Hosts: ·      Dr. Sullivan “Sully” Ayuso, Minimally Invasive Surgery, Endeavor Health (Evanston, IL), @SAyusoMD (Twitter) ·      Dr. Trevor Crafts, Minimally Invasive Surgeon, Rocky Mountain VA Medical Center (Denver, CO), @CraftsTrevor (Twitter)  ·      Dr. H. Masson Hedberg, Minimally Invasive Surgeon, Endeavor Health (Evanston, IL) ·      Dr. Michael Ujiki, Professor and Louis Biegler Chair of Surgery, Endeavor Health (Evanston, IL), @UjikiMike ·      Dr. Brian Dunkin, Chief Medical Officer at Boston Scientific, @briandunkinmd Learning Objectives:  -       Identify and Describe Common Endobariatric Procedures: Learners will be able to name and briefly describe at least three common endobariatric procedures discussed in the episode, including Endoscopic Sleeve Gastroplasty (ESG), Endoscopic GJ Revisions (Transoral Outlet Reduction - TORR/EGJR), and Intragastric Balloons, along with their historical context and evolution. -       Explain the Mechanism and Benefits of Endoscopic Sleeve Gastroplasty (ESG): Learners will be able to articulate the procedural technique of ESG, including the U-shaped suture pattern, its impact on gastric volume reduction, and the proposed mechanisms of weight loss, such as slowed gastric emptying and hormonal changes, as compared to laparoscopic sleeve gastrectomy. -       Discuss the Role of Technology and Training in Endobariatrics: Learners will be able to explain the significance of endoscopic suturing devices like the Overstitch in the advancement of endobariatric procedures and recognize the importance of specialized training, including the recommendations against fundal suturing for safety during the initial learning curve. -       Compare and Contrast Endobariatric Procedures with Surgical and Pharmacological Obesity Treatments: Learners will be able to discuss the position of endobariatric procedures as a "gap therapy" in the spectrum of obesity treatments, highlighting their benefits such as reduced invasiveness, lower complication rates, faster recovery, and increased patient access compared to surgery, as well as their potential role in conjunction with pharmacologic therapies like GLP-1 agonists. -       Recognize Key Considerations and Potential Complications of Endobariatric Procedures: Learners will be able to identify important technical considerations during ESG, such as achieving full-thickness bites while avoiding injury to adjacent organs, and describe common post-procedure issues associated with intragastric balloons, including nausea, vomiting, and the need for general anesthesia during removal. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity: https://pubmed.ncbi.nlm.nih.gov/39888616/ Surgical Endoscopy Series Ep. 1: An Introduction to Surgical Endoscopy: https://app.behindtheknife.org/podcast/surgical-endoscopy-series-ep-1-an-introduction-to-surgical-endoscopy Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

SUMMARYIn this episode of "Right About Now," host Ryan Alford and co-host Chris Hansen discuss key business news, including Donald Trump's address to Congress, the discontinuation of Skype, and the impact of tariffs on the U.S. economy. They reflect on the decline of Skype in favor of platforms like Zoom and WhatsApp, and explore the evolving job market influenced by AI. The conversation also touches on the importance of diversity in hiring, the benefits of entrepreneurship, and the volatile nature of cryptocurrency markets. The episode emphasizes staying informed and adaptable in a rapidly changing economic landscape.TAKEAWAYSBusiness news highlights and current events overviewKey takeaways from Donald Trump's address to CongressImplications of tariffs on the U.S. economyDiscontinuation of Skype and its impact on communicationPolitical climate and its influence on business decisionsEconomic insights, including discussions on tax cutsDiversity in hiring practices and merit-based hiringThe role of technology and AI in the job marketThe importance of entrepreneurship and brand building on social mediaThe evolving landscape of communication platforms and their alternatives If you enjoyed this episode and want to learn more, join Ryan's newsletter https://ryanalford.com/newsletter/ to get Ferrari level advice daily for FREE. Learn how to build a 7 figure business from your personal brand by signing up for a FREE introduction to personal branding https://ryanalford.com/personalbranding. Learn more by visiting our website at www.ryanisright.comSubscribe to our YouTube channel www.youtube.com/@RightAboutNowwithRyanAlford.

In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Antipsychotic Withdrawal Syndrome: Symptoms, Risks, and Prevention Strategies

“Behind the Evidence” is the addiction medicine podcast of the Grayken Center for Addiction at Boston Medical Center, and a project of the Center's free bimonthly newsletter Alcohol, Other Drugs, and Health: Current Evidence (AODH). This episode was recorded in June 2024 and features an interview with Joao P. De Aquino, MD on his article published in the American Journal of Drug and Alcohol Abuse: “The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.” And an interview with Donovan Maust, MD on his article in JAMA Network Open: “Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy.” Click the following links to read AODH's summaries of Dr De Aquino and Dr. Maust's articles.Also discussed: Christine PJ, Lodi S, Hsu HE, et al. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024;119(7):1313-1321.Hosts: Honora L. Englander, MD and Marc R. Larochelle, MDProduction: Raquel Silveira, MBAEditing: Casy Calver, PhDMusic and cover art: Mary Tomanovich, MAMiriam Komaromy, MD is the Medical Director of the Grayken Center for Addiction, and co-Editor-in-Chief of AODH, together with David Fiellin, MD.Learn more about AODH and subscribe for free at www.aodhealth.org“Behind the Evidence” is supported by the Grayken Center for Addiction at Boston Medical Center. It is intended for educational purposes only, and should not be considered medical advice. The views expressed here are our own, and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

Medboard EU EU MDR and IVDR article 10a - Discontinuation of Supply: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02017R0745-20250110#art_10a EU IVDR transition periods - Visual: https://health.ec.europa.eu/document/download/ff7fa114-c539-46b3-9066-4bfbb306e9de_en?filename=timeline_ivdr_en.pdfEUDAMED EMDN: UPDATE or not to UPDATE - MDCG 2024-2 Rev 1 and 2021-12 Rev 1 : https://health.ec.europa.eu/document/download/ff8d6bf6-785f-48e1-beaf-2cfe13f59fd7_en?filename=mdcg_2025-2_en.pdf MDCG 2024-2: https://health.ec.europa.eu/document/download/de470384-e8be-45e7-a334-226757f8816d_en?filename=mdcg_2024-2_en.pdf MDCG 2021-12: https://health.ec.europa.eu/document/download/d90b3f63-1d62-43e6-bf5f-fb32ea7c47a2_en?filename=md_2021-12_en.pdf Contact points of National Authorities - Bookmark them in case: https://health.ec.europa.eu/document/download/c28e965a-3b7c-4a5b-a6ee-d1724d06f20d_en?filename=md_contact_points_of_national_authorities.pdf EU Battery 2023/1542 - Guidance issued by EU commission: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:C_202500214 Swiss Maintenance of Medical Devices - Guidance for Hospitals: https://www.swissmedic.ch/swissmedic/en/home/medical-devices/reprocessing---maintenance/maintenance.html UK timeline for UKCA - Be ready for 2030: https://assets.publishing.service.gov.uk/media/6718b88738149ce9d09e3894/Infographic_-_Devices_transition_timeline.pdf UK Post-Market Surveillance - Implementation and Template of PSUR: https://www.gov.uk/government/publications/medical-devices-post-market-surveillance-requirements/the-medical-devices-post-market-surveillance-requirements-amendment-great-britain-regulations-2024-guidance-on-implementation https://assets.publishing.service.gov.uk/media/67813b39363ac763c8ede498/Medical_devices_periodic_safety_update_report__PSUR__formatting__1_.pdf PMS Guidance: https://www.gov.uk/government/publications/medical-devices-periodic-safety-update-report-psur/the-medical-devices-post-market-surveillance-requirements-amendment-great-britain-regulations-2024-guidance-on-periodic-safety-update-reports PMS Requirements: https://www.gov.uk/government/publications/medical-devices-post-market-surveillance-requirements/post-market-surveillance-requirements-for-medical-devices-summary-of-main-changes PMS Obligations per device type: https://www.gov.uk/government/publications/medical-devices-post-market-surveillance-requirements/post-market-surveillance-pms-obligations-by-medical-device-type   TUK Vigilance Reporting - Field Safety notices and Example of incidents: https://www.gov.uk/government/publications/medical-devices-examples-of-reportable-incidents FSN: https://www.gov.uk/guidance/effective-field-safety-notices-fsns-guidance-for-manufacturers-of-medical-devices#full-publication-update-history Devices for cardiac ablation: https://www.gov.uk/government/publications/reporting-adverse-incidents-devices-for-cardiac-ablation Joint Replacement implant: https://www.gov.uk/government/publications/reporting-adverse-incidents-joint-replacement-implants#full-publication-update-history Intraocular lenses: https://www.gov.uk/government/publications/reporting-adverse-incidents-intraocular-lenses Insulin pumps and meter systems: https://www.gov.uk/government/publications/reporting-adverse-incidents-insulin-pumps-and-meter-systems   UK guide for IVD - Learn before to re-learn: https://assets.publishing.service.gov.uk/media/67863a313ef063b15dca0f47/Guidance_on_the_regulation_of_IVD_medical_devices_in_GB.pdf Training EU MDR training - Green Belt Certification Program: https://school.easymedicaldevice.com/course/gb33/ Rest of the World: Laboaratory Developed Tests FAQ - Learn all about LDTs: https://www.fda.gov/medical-devices/laboratory-developed-tests-faqs/definitions-and-general-oversight-laboratory-developed-tests-faqs and https://www.fda.gov/medical-devices/laboratory-developed-tests-faqs/medical-device-reporting-complaints-and-corrections-removals-reporting-laboratory-developed-tests How to apply your dossier in Australia - Full guidance by TGA: https://www.tga.gov.au/how-we-regulate/manufacturing/manufacture-medical-device/obtain-and-maintain-regulatory-evidence/australian-regulatory-evidence-options-medical-device-application/tga-conformity-assessment-certification/application-instructions-conformity-assessment Malaysia guidance for HIV Self-test - Placement on the Malaysia Market: https://www.mda.gov.my/index.php/documents/ukk/3480-final-gd-placement-of-hiv-self-test-kit-in-malaysia-market-2nd-edition-pdf/file Import Medical Device for Personnal Use in Malaysia - What means Personal use? https://portal.mda.gov.my/index.php/documents/ukk/3468-draft-public-comment-gd-importation-of-medical-device-for-personal-use-second-edition-updated-2025-pdf/file Alert by Philippines for Product registration - Engaging consultants is not encouraged: https://www.fda.gov.ph/wp-content/uploads/2025/01/FDA-Advisory-No.2025-0033-.pdf Saudi Arabia clearance of Medical Devices - For trainings or conferences: https://www.sfda.gov.sa/sites/default/files/2025-01/Guide%20to%20Conditions%20and%20requirements%20for%20Clearing%20food%2C%20Medical%20devices%2C%20and%20cosmetics%20for%20exhibitions%2C_1.pdf China Medical Device Regulations Round-up 2024 - Cisema.com video: 2024 Round-Up of China Medical Device regulations India update classification lists - List available: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTIzNDI= Podcast Episode 318 - How to register a Medical Device in South Africa - Khanysile Nkuku : https://podcast.easymedicaldevice.com/318-2/ Episode 319 - How to perform your PMS for a Drug-Device Combination - Joan D'Souza: https://podcast.easymedicaldevice.com/319-2/ Episode 320 - Top 5 common NCs on an ISO 13485 audit: https://podcast.easymedicaldevice.com/320-2/ Episode 321 - 6 Tips to grow as a QA RA Manager: https://podcast.easymedicaldevice.com/321-2/

A Rebelião Saudável nasceu da união de diversos profissionais de saúde que pensam diferente e cujo foco é promover saúde e bem estar, com comida de verdade e sem medicamentos. Semanalmente a Rebelião se reune no app Telegram para discussão de tópicos importantes relacionados a Nutrição Humana e Qualidade de vida. Nessa semana, conversamos sobre Agonistas de GLP-1. Referências citadas na transmissão: Itoh Y, Tani M, Takahashi R, Yamamoto K. Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide. Diabetol Int. 2024 Sep 9;15(4):850-854. doi: 10.1007/s13340-024-00751-4. PMID: 39469548; PMCID: PMC11512937. Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, Rajpathak S, Iglay K. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Patient Prefer Adherence. 2020 Nov 27;14:2337-2345. doi: 10.2147/PPA.S277676. PMID: 33273810; PMCID: PMC7708309. Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Garvey WT. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023 Mar;31(3):703-715. doi: 10.1002/oby.23673. Epub 2023 Jan 18. PMID: 36655300. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185. Hengist A, Sciarrillo CM, Guo J, Walter M, Hall KD. Gut-derived appetite hormones do not explain energy intake differences in humans following low-carbohydrate versus low-fat diets. Obesity (Silver Spring). 2024 Sep;32(9):1689-1698. doi: 10.1002/oby.24104. Epub 2024 Aug 7. PMID: 39113385; PMCID: PMC11357890. B Liao, C Able, J Sonstein, T Kohn, (157) Prescribing Ozempic and Wegovy for Weight Loss is Associated with an Increased Risk of Erectile Dysfunction and Hypogonadism in Non-Diabetic Males, The Journal of Sexual Medicine, Volume 21, Issue Supplement_1, February 2024, qdae001.148, https://doi.org/10.1093/jsxmed/qdae001.148 Ajude a rebelião saudável! Seja um apoiador do nosso movimento e garanta que as informações transmitidas continuarão gratuitas para todos! Além de ajudar, você terá acesso a um post mensal exclusivo para apoiadores! Acesse https://apoia.se/rebeliaosaudavel e contribua com a quantia que puder! Ajude a manter esse conteúdo vivo! #facapartedarebeliao Você também pode participar da discussão e da Rebelião. Toda quarta feira, às 7:00, estaremos ao vivo no Telegram, basta acessar o nosso canal: https://t.me/RebeliaoSaudavel. Se você gosta de nosso trabalho, deixe um review 5 estrelas e faça um comentário no seu app de podcast. Essa atitude é muito importante para a Rebelião saudável e vai ajudar nosso movimento a chegar a cada vez mais pessoas. Você também pode nos acompanhar no instagram, http://www.instagram.com/henriqueautran. E em nosso canal do YouTube: https://youtube.com/c/henriqueautran.

A new year and a new beginning. Special guest co-host Pedro Mendes joins Dr. Chris Labos to answer a viewer question about menopause. Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE Email us your questions at thebodyofevidence@gmail.com. Assistant researcher: Aigul Zaripova, MD Editor: Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause- cancer Obviously, I'm not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: Geographic variability of menopausal symptoms 1) Nappi RE et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021 May 24;28(8):875-882. doi: 10.1097/GME.0000000000001793. 2) Nappi RE, et al. Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey. Maturitas. 2023 Jan;167:66-74. doi: 10.1016/j.maturitas.2022.09.006. What's the normal duration of symptoms 3) Avis NE, et al. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001/jamainternmed.2014.8063. The Women's Health Initiative (WHI) studies Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321. Anderson GL et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701-12. doi: 10.1001/jama.291.14.1701. Decline in HRT after WHI studies Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012 Sep;120(3):595-603. doi: 10.1097/AOG.0b013e318265df42. Danish Osteoporosis Prevention Study Schierbeck LL metal. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012 Oct 9;345:e6409. doi: 10.1136/bmj.e6409. Kronos Early Estrogen Prevention Study (KEEPS) Harman SM, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014 Aug 19;161(4):249-60. doi: 10.7326/M14-0353. Kronos Early Estrogen Prevention Study (KEEPS) Hodis HN et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016 Mar 31;374(13):1221-31. doi: 10.1056/NEJMoa1505241. Stopping hormonal therapy Berman RS et al. Risk factors associated with women's compliance with estrogen replacement therapy. J Womens Health. 1997 Apr;6(2):219-26. doi: 10.1089/jwh.1997.6.219. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med. 2005 Dec 19;118 Suppl 12B:163-5. doi: 10.1016/j.amjmed.2005.09.051. Tapering vs. abrupt stop or hormonal therapy Haimov-Kochman R et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause. 2006 May-Jun;13(3):370-6. doi: 10.1097/01.gme.0000186663.36211.c0. PMID: 16735933.

Welcome back Rounds Table Listeners!We are back today with a solo episode with Dr. John Fralick!This week, he will discuss a paper exploring whether Renin-Angiotensin System Inhibitors should be held before major non-cardiac surgery. Here we go!Continuation versus Discontinuation of Renin-Angiotensin System Inhibitors Before Major Non-Cardiac Surgery: The Stop-or-Not Randomized Clinical Trial (0:00 – 6:16).And for the Good Stuff:"Tweetorials" by Tony Breu (6:16 – 7:11).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Introduction: Host: Jr. Journey through the Sega systems, focusing on the Sega Dreamcast. Sega's aim to redefine gaming after the failure of the Sega Saturn. Dreamcast's sleek design, 128-bit processing power, and built-in modem for online play. The Revolutionary Dreamcast: Introduction of online gaming, a concept revolutionary at the time. Remarkable launch lineup, including Sonic Adventure and Soul Calibur. Second Network groundbreaking online capabilities. Formation of virtual communities through multiplayer games. Challenges Faced by Dreamcast: Competition from the PlayStation 2, with superior graphics and extensive game library. Breached security measures leading to rampant piracy. Revenue erosion and alienation of third-party developers. Notable Games and Legacy: Memorable games such as Jet Grind Radio, Skies of Arcadia, and Power Stone. Sega's uphill battle against competitors. Discontinuation of the Dreamcast in 2001, marking Sega's exit from the hardware business. Legacy of Dreamcast's innovation, including features like the visual memory unit and interactive fishing controller. Beloved cult classic status among collectors and gaming enthusiasts. Partnership with Xbox showcasing Sega's potential as a developer. Conclusion: Dreamcast's impact on the gaming landscape and its competitive nature. Appreciation for games like Crazy Taxi, Phantasy Star Online, and Resident Evil Code Veronica. Gratitude for Sega's contribution to the gaming industry and encouragement to seek out uncommon places in gaming.

In this episode of The ASHE Podcast, we explore how innovative approaches in infection prevention are reshaping healthcare practices. Guests Graham Snyder, Elise Martin, and Ashley Ayers join the discussion to discuss their study titled "Impact of Discontinuation of Contact Precautions on Surveillance- and Whole Genome Sequencing-Defined Methicillin-Resistant Staphylococcus aureus Healthcare-Associated Infections" and what it means for the future of infection control. The conversation explores the evolving role of contact precautions (CP) in managing MRSA transmission. The discontinuation of CP has sparked debates in infection prevention, with this study providing a fresh perspective through whole genome sequencing (WGS). Unlike traditional surveillance methods, WGS offers deeper insights into MRSA transmission dynamics, unveiling patterns that can redefine how we approach infection control in acute care settings. The study's findings revealed a surprising drop in MRSA healthcare-associated infections (HAIs) post-discontinuation of CP, raising questions about how to balance infection prevention with resource management and patient safety. By reducing reliance on CP, hospitals may gain advantages such as cost savings and fewer adverse effects for patients, without compromising care quality. Finally, the episode delves into challenges faced during the study and the need for further research to refine infection prevention strategies. Future efforts could focus on tailoring CP to specific risks and developing more precise methods for tracking and preventing MRSA transmission. Be sure to read the full article available at Cambridge.org/ASHE. And for the official SHEA recommendations for MRSA treatment and prevention visit: https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/sheaidsaapic-practice-recommendation-strategies-to-prevent-methicillinresistant-staphylococcus-aureus-transmission-and-infection-in-acutecare-hospitals-2022-update/5DB835D2E13F7E813A8A2FD7CB8386BD

In this episode, Dr. Valentin Fuster reviews a study on the impact of long-term drug treatment discontinuation in heart failure patients with reduced ejection fraction. He breaks down four pathways of drug withdrawal—ranging from immediate clinical worsening to long-term deterioration—emphasizing the importance of avoiding unnecessary interruptions in treatment to prevent significant health risks.

Welcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. Mike Fralick and Justin Boyle discuss two recent papers exploring the effect of sitting time reduction on blood pressure and the discontinuation of RAAS inhibition perioperatively. Two papers, here we go!Sitting Time Reduction and Blood Pressure in Older Adults (0:00 – 11:35).Discontinuation versus continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial (11:35 – 21:32).And for the Good Stuff:Summer McIntosh becomes 1st Canadian to win 3 gold medals at a single Olympic Games (21:32 – 22:37).One-Pagers for the Wards by Dr. Mike Fralick! (22:37 – 24:13)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode of Stokie Geeks, hosts Paul and Joe discuss a variety of topics related to cigars, including recent cybersecurity challenges, reviews of various cigar brands, and the impact of aging on cigar flavors. They delve into the nuances of lawn mulch cigars, the inconsistencies of Cuban cigars, and the evolution of brands like Tatuaje, Gurkha, and Perdomo. The conversation also touches on the importance of cigar accessories and the experiences of smoking different blends over the years. The episode concludes with reflections on the future of cigar brands and a preview of the next episode. Chapters 00:00 Exploring Cigar Ratings: Highs and Lows 17:42 Identifying Fake Cuban Cigars 20:08 The Importance of Aging Cigars 22:28 Villiger: From Machine-Made to Premium Blends 29:14 EP Carrillo's Range of Cigars: Hits and Misses 32:34 Inconsistency in the Cigar Industry: The Case of San Latino 36:39 Limited Edition Cigars: The Good, the Bad, and the Tasty 48:04 Size Matters: Finding the Right Fit for Your Palate 56:35 Changes in Ownership: Impact on Cigar Brands 01:00:53 Exploring the Taste and Construction of Various Cigars 01:03:02 The Fate of Padilla Cigars: Availability and Discontinuation 01:08:39 Exploring Cuban Cigars and Other Brands 01:13:38 Sponsor Shoutout: Havana Cigar Club 01:18:39 Reviewing Illusion 888 Slam and Other Cigars 01:22:10 The Popularity of Flor de los Antilles 01:26:59 Exploring the Zino Classic Line 01:30:33 Reviewing Alec Bradley Fine and Rare Redo 01:32:45 The Unique Gran Habano SDK Zulu Zulu 01:35:53 The Enjoyment of Cosofrin and Does Miami Reserva  

Welcome back Rounds Table Listeners!We are back today with a special Rapid Fire Podcast!This week, Drs. Mike Fralick and Justin Boyle discuss top papers from the 2024 European of Society of Cardiology Congress. Here we go!Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease (0:00 – 9:25).Beta-Blocker Interruption or Continuation after Myocardial Infarction (9:25 – 13:52).Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (13:52 – 21:20).Continuation vs. Discontinuation of Renin-Angiotensin System Inhibitors Before Major Non-Cardiac Surgery (21:20 – 28:51).Of note, for prescribers in Ontario, there is now a limited use code for finerenone for patients that have both T2DM and CKD. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode, host Alyssa Watson, DVM, is joined by fellow VetMedux colleague Jordy Waller, DVM, to discuss a recent Clinician's Brief article, “Top 7 Drug Classes to Be Tapered Before Discontinuation.” Dr. Watson and Dr. Waller dissect the article from top to bottom, pulling out their most valuable takeaways. They also share their own real world experiences with weaning drugs like steroids, prazosin, and fluoxetine.Resources:https://www.cliniciansbrief.com/article/drug-withdrawal-syndrome-opioids-veterinaryhttps://www.simparicatriodvm.com/Contact:podcast@vetmedux.comWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist

In this urgent episode of Stay Off My Operating Table, Dr. Philip Ovadia and guest Alison Smart discuss the critical issue of Levemir insulin discontinuation. Smart, a passionate advocate, reveals how this decision by Novo Nordisk threatens the health of over a million diabetes patients, particularly pregnant women, and calls listeners to action in the fight to keep this vital medication available.KEY POINTSLevemir's unique properties make it essential for precise diabetes management, especially for pregnant women and those requiring tight blood sugar controlThe discontinuation of Levemir could have global implications, affecting millions of patients worldwideCongressional action is needed to prevent the discontinuation and ensure continued access to this crucial insulin optionListeners can support the cause by contacting their representatives and supporting the Alliance to Protect Insulin ChoiceRESOURCES Alliance to Protect Insulin Choice website: https://www.alliancetoprotectinsulin.org/GoFundMe page for the Alliance to Protect Insulin Choice (link not provided in transcript)YouTube video explaining the importance of Levemir (link not provided in transcript)TIMESTAMPS00:00:00 - Introduction and background on Levemir discontinuation00:05:30 - Explaining Levemir's importance and how it differs from other insulins00:15:45 - Advocacy efforts and challenges faced00:25:20 - Impact on pregnant women and gestational diabetes00:35:10 - How listeners can help and take actionCONNECT• Alison Smart:   - Facebook: Alliance to Protect Insulin Choice  - Instagram: Alliance to Protect Insulin Choice  - Twitter: @insulinchoiceGUEST BIOAlison Smart is a dedicated advocate for insulin choice and mother of a daughter with Type 1 diabetes. She founded the Alliance to Protect Insulin Choice after learning about the planned discontinuation of Levemir insulin. Smart has been actively lobbying senators and congressional representatives to prevent the removal of thSend us a text Chances are, you wouldn't be listening to this podcast if you didn't need to change your life and get healthier. So take action right now. Book a call with Dr. Ovadia's team. One small step in the right direction is all it takes to get started. How to connect with Stay Off My Operating Table:Twitter: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Learn more about Dr. Ovadia's personalized health coaching Get Dr. Ovadia's book Stay Off My Operating Table on Amazon. Take Dr. Ovadia's metabolic health quiz: iFixHearts visit Dr. Ovadia's website: Ovadia Heart Health visit Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

EU e-IFU for medical devices - Consultation ongoing: https://ec.europa.eu/eusurvey/runner/Survey_eIFUs_medicaldevices_2024?surveylanguage=EN MDR Transition period - Visual timeline: https://health.ec.europa.eu/document/download/06bb3982-dc01-46aa-95af-d8833c9fcb21_en?filename=timeline_mdr_en.pdf Implementing Act IVDR Common specifiaction - Consultation until Sept 16th: https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/14383-In-vitro-diagnostic-medical-devices-common-specifications_en Cyber Security in Health and medicine - Results from Cyber incidents: https://op.europa.eu/o/opportal-service/download-handler?identifier=9d3355cf-591f-11ef-acbc-01aa75ed71a1&format=pdf&language=en&productionSystem=cellar&part= How much cost a Notified Body? - Links available: https://health.ec.europa.eu/document/download/ff5716d5-fe77-4f45-b883-fcf3da4acd15_en?filename=md_nbs_fees_en.pdf Switzerland Swiss Combined Studies - Information Sheet to read: https://www.swissmedic.ch/dam/swissmedic/it/dokumente/medizinprodukte/mep_urr/bw600_00_017e_mb_combined_studies.pdf.download.pdf/BW600_00_017e_MB_Information_combined_studies_KlinV_KlinVMEP.pdf 3D Printing for Medical Devices - Reminder from Swissmedic: https://www.swissmedic.ch/dam/swissmedic/en/dokumente/medizinprodukte/mep_urr/mu600_00_017d_mb_3d-drucker_mep.pdf.download.pdf/MU600_00_017e_MB_3D_printers_medical_devices.pdf Training EU MDR training September 23rd - Register Now: https://school.easymedicaldevice.com/course/gb33/ Events RAPS Convergence - September 17th to 19th California: https://medtechconf.com/event/raps-convergence-2024/ AI ACT SUMMIT - October 1st :Online : https://medtechconf.com/event/ai-act-summit/ Team-PRRC - October 17th - Malaga: https://medtechconf.com/event/team-prrc-third-annual-summit/ Afrisummit - November 3-6 - Egypt: https://www.pharmaregafrisummit.com/ Meds'd - November 7th - Berlin: https://medtechconf.com/event/medxd-medtech-meets-digital-2024/ ROW Australia Webinar: Software transition deadline on 1 November 2024 Reclassification needed: https://www.tga.gov.au/resources/event/webinars/software-reclassification-reforms-webinar-q-and-software-transition-deadline-1-november-2024   USA Voluntary malfunction Summary Reporting (VSMR) - Support the system: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/voluntary-malfunction-summary-reporting-vmsr-program-manufacturers FDA Webinar: Remanufacturing of Devices - Distinction between servicing and remanufacturing: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/webinar-final-guidance-remanufacturing-medical-devices-09102024?utm_source=FDALinkedin FDA DeNovo - Electronic Submission template: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-de-novo-requests PCCP Draft Guidance - Plan your changes so they don't need a review again: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/predetermined-change-control-plans-medical-devices   Brazil Brazil UDI project - The world will be UDI soon: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/saiba-mais-sobre-o-projeto-de-identificacao-unica-de-dispositivos-medicos Brazil Vigilance Reporting - e-Notivisa Launch: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/cidadaos-poderao-notificar-eventos-adversos-de-dispositivos-medicos-pelo-e-notivisa   Singapore Singapore Change Management Program - Consultation on SaMD Guidance: https://www.hsa.gov.sg/announcements/regulatory-updates/consultation-on-guidance-on-change-management-program-(cmp)-for-samd   Bahrain Guidance for registration of Medical Devices - Screenshot included: https://www.nhra.bh/Departments/MDR/MediaHandler/GenericHandler/documents/departments/MDR/guidelines/Medical%20Device%20Importation%20Guideline-%20Ver%2011.1.pdf   Medical Device Live Expert: Medical Device Live Expert - July August: MDLE #2 - US EXPERT: Medical Device Live Expert #2 – US is in the place MDLE #3 - EU MDR and IVDR Future: MDLE #3 - The Future of the MDR in EU, What Is?   Podcast Podcast Nostalgia - July and August AI ACT - What are the challenges for Medical Devices? Fabien Roy https://podcast.easymedicaldevice.com/292-2/ EU Battery Regulation - How to be ready? Erik Vollebregt: https://podcast.easymedicaldevice.com/293-2/ How to register your Medical Device in the UAE? Ahmed Hendawy: https://podcast.easymedicaldevice.com/294-2/ EU MDR majow update: Interruption or Discontinuation of Supply! Erik Vollebregt: https://podcast.easymedicaldevice.com/295-2/ IVDR Class D - Lesson learned from Notified Bodies. Andreas Stange: https://podcast.easymedicaldevice.com/296-2/ How to use Harmonised Standards for Devices? Beat Keller: https://podcast.easymedicaldevice.com/297-2/ Manage the Transfer/Renewal/ Surveillance/Change of your CE Certificate. Ralf Gansel: https://podcast.easymedicaldevice.com/298-2/ How to grow from Zero to Hero in Medical Device? Stephan O'Rourke: https://podcast.easymedicaldevice.com/299-2/ Episode 300: How to use AI GPT for your QA RA work? Martin King: https://podcast.easymedicaldevice.com/300-2/

JAMA Editor in Chief Kirsten Bibbins-Domingo reviews 4 JAMA trials presented at this year's European Society of Cardiology (ESC) Congress on antihypertensive continuation before elective surgery, potassium supplementation after cardiac surgery, pulmonary vein isolation for symptomatic atrial fibrillation, and a triple-drug combination pill for resistant hypertension in Africa. Related Content: Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria Is a Low-Dose Triple-Drug Combination Pill Protocol the Answer for Hypertension Control in Sub-Saharan Africa? Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation

Guideline evolution is driven by ongoing research; recent studies like PeriOperative ISchemic Evaluation-3 Trial (POISE-3) and trials such as OPtimisation of Peri-operaTive CardIovascular Management to Improve Surgical outcomE II (OPTIMISE II) trial may influence recommendations on hemodynamic management and the use of tranexamic acid. Future guidelines are expected to integrate machine learning models for risk prediction, addressing complex patient phenotypes and interactions. Discontinuation vs. continuation of renin–angiotensin system inhibition before non-cardiac surgery: the SPACE trial has challenged existing practices regarding the discontinuation of ACE inhibitors or ARBs, highlighting the dynamic nature of medical guidelines and the continuous incorporation of new evidence to enhance patient care. Presented by Andy Cumpstey and Joff Lacey with Mark Edwards, Consultant in Anaesthesia and Perioperative Medicine, University Hospital Southampton Honorary Senior Clinical Lecturer, University of Southampton and John Whittle, Clinical Academic working in Perioperative Translational Medicine at UCL and Honorary Consultant in Perioperative Medicine, Anaesthesia and Critical Care at University College Hospitals London. -- More on POISE-3 here: https://clinicaltrials.gov/study/NCT03505723 More on OPTIMISE II here: https://optimiseii.org/ More on the SPACE trial here: https://doi.org/10.1093/eurheartj/ehad716  

Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.

Episode #303 Summary Actor Daryl Mitchell stop by Reza Rifts to chat about what he is up to and some of his most memorable roles. He is known for his roles in movies like Galaxy Quest and TV shows like NCIS: New Orleans. We discuss Daryl's experience in stand-up comedy, working with comedy legends like Steve Martin and Tim Allen, and his involvement in the Daryl Mitchell Foundation, which aims to provide resources and information for people with disabilities. Daryl also shares his love for Comic-Cons and his desire to do a sequel to Galaxy Quest.   Daryl's Socials IG https://www.instagram.com/darylchillmitchell/  X https://twitter.com/darylchillmitch  YT https://www.youtube.com/user/darylchill2000  Chapters 00:00 Introduction and Background 04:22 The Making of House Party 07:46 The Success of House Party and Working with Julie Bowen 11:38 Working with Mike Starr and Julie Bowen 15:23 The Importance of Cherishing Memories 17:44 Involvement in Writing and Producing 19:10 The Discontinuation of Brothers 20:55 The Potential for a Galaxy Quest Sequel 22:24 Working with Comedy Greats in Sergeant Bilko 23:50 The Unfamiliarity with Comic-Cons 25:17 The Experience of Being Shot in Galaxy Quest 27:12 The Success and Impact of 10 Things I Hate About You 28:09 The Intensity of Crime Show Storylines 29:03 Working with Great Actors and Comedians 30:00 The Desire for a Galaxy Quest Sequel 31:28 The Darryl Mitchell Foundation and Supporting People with Disabilities 32:55 The Fascination with Comic-Cons 36:24 The Desire for a Galaxy Quest Sequel 39:41 Promoting the Darryl Mitchell Foundation 42:36 Conclusion Takeaways

"The REAL Battle of the Sexes": The Punch Junkie™ Podcast (8.1.2024)1️⃣ The Discontinuation of Boxing from Future Olympics:

The EU MDR is still not stable. There are still updates ongoing so stay tuned and listen to Erik Vollebregt explaining the Article 10a that will be integrated to the EU MDR where medical device manufacturers have to inform about interruption of supply. So what will be the requirements and what should you do. Listen to it to know more.  Who is Erik Vollebregt?  Erik specializes in EU and national legal and regulatory issues relating to medical devices, including eHealth, mHealth, software, and protection of personal data. He is an expert in life sciences regulation at the EU and Dutch level, with a focus on contracts, and regulatory litigation against competent authorities and M&A. Erik was initially trained as intellectual property and competition lawyer, starting his career at the Directorate-General for Competition of the European Commission. He subsequently gained experience in contentious matters, commercial contracts, and transactional work at three large international law firms. He actively contributes to law and policy development at the national and EU levels via membership in specialized committees at branch associations and the European Commission. Erik also works as an arbitrator in medical devices-related disputes and is regularly retained as an expert witness in foreign litigation. Erik worked and lived in Brussels and Stockholm for several years, and is fluent in Dutch, English, French, German, and Swedish. Chambers Europe 2017: Erik is known for his specialism in regulatory work, which covers medical technology, devices, and products as well as for biotechnology. Clients confirm his strong capabilities, with one saying “he stands out to me. Whenever I work with lawyers he has been the best, with a solid scientific background. He has the perfect combination of skills and experience.”   Who is Monir El Azzouzi?  Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland.  Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  Link Erik Vollebregt Linkedin Profile: https://www.linkedin.com/in/erikvollebregt/ Axon Lawyers Website: https://www.axonlawyers.com/  EU MDR: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02017R0745-20230320  Medical devices: Council adopts new measures to help prevent shortages    https://data.consilium.europa.eu/doc/document/PE-54-2024-INIT/en/pdf  Article Judith de Wildth – How to prepare for article 10a: https://www.linkedin.com/posts/erikvollebregt_how-to-prepare-for-article-10a-mdr-as-a-manufacturer-activity-7216378083308646401-vqzF  EUDAMED roll-out timeline: https://health.ec.europa.eu/document/download/04ce2012-97df-4dd0-8a39-d4f6993b9e16_en?filename=md_eudamed_roadmap_en.pdf  Social Media to follow Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi Twitter: https://twitter.com/elazzouzim Pinterest: https://www.pinterest.com/easymedicaldevice Instagram: https://www.instagram.com/easymedicaldevice

First off, Apple and the EU clash over withheld features due to the DMA, sparking debate on Apple's motives and implications for their EU relations. Then, Chuck Joiner, David Ginsburg, Brian Flanigan-Arthurs, Marty Jencius, Jim Rea, Web Bixby, Jeff Gamet, Eric Bolden, and Mark Fuccio look at a reason for the discontinuation of Apple Card's buy now, pay later feature. Finally, the panel members consider the proposed smartphone ban in California schools, emphasizing responsible tech use, balanced teaching methods, and leveraging technology for learning in educational settings.  MacVoices is supported by ExpressVPN. High speed, ultra secure, and easy to use. Take back your online privacy while you surf. Visit ExpressVPN/MacVoices and find out how to get three months free. Show Notes: Chapters: 00:00 Introduction 00:52 Apple's Stance on EU Regulations 19:38 Comparing EU Regulations to Personal Relationships 26:39 Implications of Banning Smartphones in Schools Links: Apple Intelligence and other features won't launch in the EU this year https://arstechnica.com/gaming/2024/06/apple-intelligence-and-other-features-wont-launch-in-the-eu-this-year/ Apple: Some New Features Don't Come To EU Due To The DMA https://sixcolors.com/link/2024/06/apple-some-new-features-wont-come-to-eu-due-to-the-dma/ Commentary by Steve Troughto-Smith on Apple and EU https://mastodon.social/@stroughtonsmith/112671863779186767 Apple Pay Later withdrawal likely because of a law passed in 1968 https://9to5mac.com/2024/06/19/apple-pay-later-withdrawal-reason/ Smartphone ban in schools backed by California governor  https://9to5mac.com/2024/06/21/smartphone-ban-in-schools-california/ Guests: Web Bixby has been in the insurance business for 40 years and has been an Apple user for longer than that.You can catch up with him on Facebook, Twitter, and LinkedIn. Eric Bolden is into macOS, plants, sci-fi, food, and is a rural internet supporter. You can connect with him on Twitter, by email at embolden@mac.com, on Mastodon at @eabolden@techhub.social, on his blog, Trending At Work, and as co-host on The Vision ProFiles podcast. Brian Flanigan-Arthurs is an educator with a passion for providing results-driven, innovative learning strategies for all students, but particularly those who are at-risk. He is also a tech enthusiast who has a particular affinity for Apple since he first used the Apple IIGS as a student. You can contact Brian on twitter as @brian8944. He also recently opened a Mastodon account at @brian8944@mastodon.cloud. Mark Fuccio is actively involved in high tech startup companies, both as a principle at piqsure.com, or as a marketing advisor through his consulting practice Tactics Sells High Tech, Inc. Mark was a proud investor in Microsoft from the mid-1990's selling in mid 2000, and hopes one day that MSFT will be again an attractive investment. You can contact Mark through Twitter, LinkedIn, or on Mastodon. Jeff Gamet is a technology blogger, podcaster, author, and public speaker. Previously, he was The Mac Observer's Managing Editor, and the TextExpander Evangelist for Smile. He has presented at Macworld Expo, RSA Conference, several WordCamp events, along with many other conferences. You can find him on several podcasts such as The Mac Show, The Big Show, MacVoices, Mac OS Ken, This Week in iOS, and more. Jeff is easy to find on social media as @jgamet on Twitter and Instagram, jeffgamet on LinkedIn., @jgamet@mastodon.social on Mastodon, and on his YouTube Channel at YouTube.com/jgamet. David Ginsburg is the host of the weekly podcast In Touch With iOS where he discusses all things iOS, iPhone, iPad, Apple TV, Apple Watch, and related technologies. He is an IT professional supporting Mac, iOS and Windows users. Visit his YouTube channel at https://youtube.com/daveg65 and find and follow him on Twitter @daveg65 and on Mastodon at @daveg65@mastodon.cloud. Dr. Marty Jencius has been an Associate Professor of Counseling at Kent State University since 2000. He has over 120 publications in books, chapters, journal articles, and others, along with 200 podcasts related to counseling, counselor education, and faculty life. His technology interest led him to develop the counseling profession ‘firsts,' including listservs, a web-based peer-reviewed journal, The Journal of Technology in Counseling, teaching and conferencing in virtual worlds as the founder of Counselor Education in Second Life, and podcast founder/producer of CounselorAudioSource.net and ThePodTalk.net. Currently, he produces a podcast about counseling and life questions, the Circular Firing Squad, and digital video interviews with legacies capturing the history of the counseling field. This is also co-host of The Vision ProFiles podcast. Generally, Marty is chasing the newest tech trends, which explains his interest in A.I. for teaching, research, and productivity. Marty is an active presenter and past president of the NorthEast Ohio Apple Corp (NEOAC). Jim Rea built his own computer from scratch in 1975, started programming in 1977, and has been an independent Mac developer continuously since 1984. He is the founder of ProVUE Development, and the author of Panorama X, ProVUE's ultra fast RAM based database software for the macOS platform. He's been a speaker at MacTech, MacWorld Expo and other industry conferences. Follow Jim at provue.com and via @provuejim@techhub.social on Mastodon. Support:      Become a MacVoices Patron on Patreon      http://patreon.com/macvoices      Enjoy this episode? Make a one-time donation with PayPal Connect:      Web:      http://macvoices.com      Twitter:      http://www.twitter.com/chuckjoiner      http://www.twitter.com/macvoices      Mastodon:      https://mastodon.cloud/@chuckjoiner      Facebook:      http://www.facebook.com/chuck.joiner      MacVoices Page on Facebook:      http://www.facebook.com/macvoices/      MacVoices Group on Facebook:      http://www.facebook.com/groups/macvoice      LinkedIn:      https://www.linkedin.com/in/chuckjoiner/      Instagram:      https://www.instagram.com/chuckjoiner/ Subscribe:      Audio in iTunes      Video in iTunes      Subscribe manually via iTunes or any podcatcher:      Audio: http://www.macvoices.com/rss/macvoicesrss      Video: http://www.macvoices.com/rss/macvoicesvideorss

How many patients maintain weight loss 1 year after discontinuing semaglutide or liraglutide? Find out about this and more in today's PeerDirect Medical News Podcast.

Sky's voice, Copilot+ Surface devices, Car Thing's discontinuation OpenAI didn't copy Scarlett Johansson's voice for ChatGPT, records show China's latest answer to OpenAI is 'Chat Xi PT' Microsoft unveils Copilot+ PCs with generative AI capabilities baked in Pioneering instant messaging program ICQ is finally shutting down after nearly 30 years Google scrambles to manually remove weird AI answers in search Rabbit Holed Elon Musk says AI will take all our jobs A jury hands Bungie a victory in a landmark anti-cheating decision Atari Acquires Intellivision Brand Congress Just Made It Basically Impossible to Track Taylor Swift's Private Jet Spotify is going to break every Car Thing gadget it ever sold Kabosu, Shiba Inu dog who inspired 'Doge' meme, dies at 18 Bitcoin pizza day C. Gordon Bell, Creator of a Personal Computer Prototype, Dies at 89 Host: Leo Laporte Guests: Christina Warren, Wesley Faulkner, and Alex Wilhelm Download or subscribe to this show at https://twit.tv/shows/this-week-in-tech Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: expressvpn.com/twit canary.tools/twit - use code: TWIT NetSuite.com/TWIT bitwarden.com/twit IntouchCX.com/twit

Sky's voice, Copilot+ Surface devices, Car Thing's discontinuation OpenAI didn't copy Scarlett Johansson's voice for ChatGPT, records show China's latest answer to OpenAI is 'Chat Xi PT' Microsoft unveils Copilot+ PCs with generative AI capabilities baked in Pioneering instant messaging program ICQ is finally shutting down after nearly 30 years Google scrambles to manually remove weird AI answers in search Rabbit Holed Elon Musk says AI will take all our jobs A jury hands Bungie a victory in a landmark anti-cheating decision Atari Acquires Intellivision Brand Congress Just Made It Basically Impossible to Track Taylor Swift's Private Jet Spotify is going to break every Car Thing gadget it ever sold Kabosu, Shiba Inu dog who inspired 'Doge' meme, dies at 18 Bitcoin pizza day C. Gordon Bell, Creator of a Personal Computer Prototype, Dies at 89 Host: Leo Laporte Guests: Christina Warren, Wesley Faulkner, and Alex Wilhelm Download or subscribe to this show at https://twit.tv/shows/this-week-in-tech Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: expressvpn.com/twit canary.tools/twit - use code: TWIT NetSuite.com/TWIT bitwarden.com/twit IntouchCX.com/twit

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, spoke about several relevant topics regarding Alzheimer care as new novel therapeutics emerge. He talked about the lessons learned from the recent discontinuation of aducanumab, and the potential and limitations lecanemab (Leqembi; Eisai) and donanemab (Eli Lilly) may bring. Additionally, he provided comments about what matters to patients, the perception of the FDA approval process, and what is considered "clinically meaningful." Furthermore, he gave perspective on ways to improve drug development and emphasized the need for policy decisions to be based on scientific evidence and not by sensationalized headlines. Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page. Episode Breakdown: 1:10 – Promise in the Alzheimer field in 2024 4:05 – Ways of improving efficiencies with drug develpment 9:10 – Discontinuation of aducanumab 11:10– Neurology News Minute 13:50 – Lessons learned from aducanumab, antiamyloid therapies  22:10– Conversations between clinicians and patients surrounding expectations/limitations of antiamyloid therapies and available treatments The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Agrees to New Specialized Protocol for Phase 3b Study of ALS Agent NurOwn FDA Approves Alternate Administration Routes for Antiseizure Medication Cenobamate Extended Use of Investigational Agent IPX203 Safe in Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Joe's Premium Subscription: www.standardgrain.comGrain Markets and Other Stuff Links-Apple PodcastsSpotifyGoogleTikTokYouTubeFutures and options trading involves risk of loss and is not suitable for everyone.China's Potential Retaliation Against US Grain Imports: US Agriculture Secretary Tom Vilsack suggests China may favor Brazilian corn and soybeans due to recent legislation limiting US farmland ownership; Chinese imports of US agricultural products decrease by $6 billion in the first quarter, prompting Vilsack to advocate for diversifying export markets away from China.

Discover the latest Amazon update as Steven Pope delve into the discontinuation of the Manage Your Customer Engagement (MYCE) tool. Learn about the features it offered, how it impacted Amazon sellers, and why it's being terminated. Steven Pope also explore Amazon's history with seller tools, the increasing challenges of selling on Amazon, and what this means for the future of seller-customer interaction. Whether you're an established Amazon seller or new to the platform, this video provides valuable insights into navigating Amazon's evolving marketplace. Don't forget to subscribe for more Amazon news and strategies.→ The Amazon Agency That Gets Results ↳ https://myamazonguy.com/amazon-agency/ → Save 20% on your first 6 months of Helium 10! ↳ Use code STEVENPOPE6M20 at https://bit.ly/3RTm5id → Already have Helium 10? ↳ Exclusive MAG discount for upgrading existing accounts at https://myamazonguy.com/h10upgrade → More reason to invest in Helium 10! ↳ https://myamazonguy.com/helium-10-service/→ Amazon Brand Registry Tools ↳ https://myamazonguy.com/amazon-brand-registry/ Timestamps:00:00 - Introduction to Amazon Email Marketing Tool Termination00:22 - Official Announcement: End of Manage Your Customer Engagement Tool00:45 - Overview of What the Tool Offered01:12 - Analysis of Amazon's Tool Development Strategy01:34 - The Requirement for Customer Engagement via the Tool02:01 - Upselling Opportunities with the Tool02:15 - No Replacement Expected for the Discontinued Tool02:27 - The Growing Difficulty of Selling on Amazon03:02 - Final Thoughts on the Discontinuation and Future Speculations03:33 - Subscribe for More Amazon UpdatesJoin My Amazon Guy on LinkedIn:https://www.linkedin.com/company/28605816/Follow us:Twitter: https://twitter.com/myamazonguyInstagram: https://www.instagram.com/stevenpopemag/Pinterest: https://www.pinterest.com/myamazonguys/Please subscribe to the podcast at: https://podcast.myamazonguy.comApple Podcast: https://podcasts.apple.com/us/podcast/my-amazon-guy/id1501974229Spotify: https://open.spotify.com/show/4A5ASHGGfr6s4wWNQIqyVwSupport the show

Apple's recent decision to discontinue support for iPhone web apps in the European Union has sparked potential investigative action from the European Commission. Citing compliance with the EU's Digital Markets Act, which mandates support for third-party browser engines, Apple plans to downgrade web apps to function similarly to bookmarks in iOS 17.4. The company attributes … Continue reading Apple's Public Web App Discontinuation in EU Draws Criticism #1726 → The post Apple's Public Web App Discontinuation in EU Draws Criticism #1726 appeared first on Geek News Central.

News InDesign 19.2 fixes some issues Discontinuation of Creative Cloud Synced files The InDesign + Long Documents Summit (use discount code CPSECRETS for $100 off!) CreativePro Week (use CPSECRETS for $100 off any multi-day pass) Julie Shaffer Shaffer Creative Certified Professional Services Marketer (CPSM) program, from SMPS: https://www.smps.org/certification/ Interview with Julie Shaffer, Certified Marketing Pro Don't Let Adobe InDesign/InCopy Notes Go Unnoticed Secrets of the Scripts Panel What Do the Default Sample Scripts Do in InDesign? Community Scripts for All Organizing Scripts into Folders Managing InDesign Scripts Easily manage dozens of scripts among multiple InDesign versions (from InDesign Tips for Design Geeks) Unicode Injector: such a cool script! Assigning Keyboard Shortcuts to Scripts Using Quick Apply to Run Scripts Obscure Feature of the Week: Wavy How to Fix the Fill on Items with Wavy Strokes InDesign How-to: Use Conditional Text More articles on Conditional Text

Join L. Joseph Parker, a research physician, as we explore a recent comparative effectiveness study that investigates the impact of discontinuing long-term benzodiazepine therapy on patients' mortality and adverse events, especially when considering their baseline opioid exposure. Discover the key findings, implications, and the potential risks and benefits associated with benzodiazepine discontinuation in patients prescribed for stable long-term treatment. L. Joseph Parker is a research physician. He discusses the KevinMD article, "Redefining medical caution: How recent studies challenge benzodiazepine prescription norms." Our presenting sponsor is Nuance, a Microsoft company. Do you spend more time on administrative tasks like clinical documentation than you do with patients? You're not alone. Clinicians report spending up to two hours on administrative tasks for each hour of care provided. Nuance, a Microsoft company, is committed to helping clinicians restore the balance with Dragon Ambient eXperience – or DAX for short. DAX is an AI-powered, voice-enabled solution that helps physicians cut documentation time in half. DAX Copilot combines proven conversational and ambient AI with the most advanced generative AI in a mobile application that integrates directly with your existing workflows. DAX Copilot can be easily enabled within the workflow of the Dragon Medical application to bring the power of ambient technology to more clinicians faster while leveraging the proven and powerful capabilities used by over 550,000 physicians. Explore DAX Copilot today. Visit https://nuance.com/daxinaction to see a 12-minute DAX Copilot demo. Discover clinical documentation that writes itself and reclaim your work-life balance. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://earnc.me/gImuWR Powered by CMEfy.

Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?Links: How a Canadian scientist and a venomous lizard helped pave the way for Ozempic The Discovery and Development of Liraglutide and Semaglutide Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor Insurers clamping down on doctors who prescribe Ozempic for weight lossOzempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most    Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean areaSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityReal-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UKSafety of SemaglutideSemaglutide for the treatment of overweight and obesity: A reviewOnce-Weekly Semaglutide in Adolescents with ObesitySemaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary DiseasesReal-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United StatesMedications and conditions associated with weight loss in patients prescribed semaglutide based on real-world dataThanks to Doctor Dreamchip for our lovely theme song!Support the show